Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.67)
# 4,114
Out of 5,150 analysts
57
Total ratings
31.25%
Success rate
-29.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $1.95 | +105.13% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.25 | +300.00% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $6.65 | +65.41% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $20.16 | +53.77% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.44 | +1,219.44% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $17.84 | +17.71% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.69 | -12.13% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.69 | +846.75% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.79 | +15,003.84% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $25.50 | -1.96% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.54 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $0.94 | +212,665.96% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.50 | +366.67% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.99 | +43.06% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $12.98 | +362.25% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.06 | +466.04% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.40 | +194.12% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.74 | +13,693.10% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.34 | +7,677.78% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.80 | +71,328.57% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.60 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.05 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.03 | +132.56% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $8.50 | +123,429.41% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.70 | +1,270.37% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $71.11 | +321.88% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $787.50 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $98.86 | -9.97% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $133.44 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.73 | +19,321.97% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.13 | +335.84% | 1 | Mar 19, 2020 |
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.95
Upside: +105.13%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.25
Upside: +300.00%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.65
Upside: +65.41%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $20.16
Upside: +53.77%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.44
Upside: +1,219.44%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $17.84
Upside: +17.71%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.69
Upside: -12.13%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.69
Upside: +846.75%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.79
Upside: +15,003.84%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $25.50
Upside: -1.96%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $57.54
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $0.94
Upside: +212,665.96%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.50
Upside: +366.67%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $6.99
Upside: +43.06%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $12.98
Upside: +362.25%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.06
Upside: +466.04%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.40
Upside: +194.12%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.74
Upside: +13,693.10%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.34
Upside: +7,677.78%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.80
Upside: +71,328.57%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $12.60
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $9.03
Upside: +132.56%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $8.50
Upside: +123,429.41%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.70
Upside: +1,270.37%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $71.11
Upside: +321.88%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $787.50
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $98.86
Upside: -9.97%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $133.44
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.73
Upside: +19,321.97%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.13
Upside: +335.84%